GlassScriptPhysician profile
Thomas R Swift
NPI 1336234459
$787.86
in general payments reported to CMS, 2019-2025
18 companies · $76.30 in 2025
The $76.30 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $52.67 · 2021: $73.81 · 2022: $33.61 · 2023: $39.27 · 2024: $224 · 2025: $76.30.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $339.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $103.09 | 2019 | |
| Abbott Laboratories | $101.36 | 2024 | Eterna |
| Abbvie INC. | $92.85 | 2021-2025 | Botox |
| Amgen INC. | $82.03 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $77.28 | 2019-2024 | Austedo Xr |
| Biogen, INC. | $58.38 | 2019-2025 | Spinraza |
| Ucb, INC. | $53.10 | 2024-2025 | Zilbrysq, Rystiggo |
| Tanabe Pharma America, INC. | $30.17 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.94 | 2019 | |
| Allergan, INC. | $25.38 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $23.00 | 2023 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $21.02 | 2024 | Hyqvia |
| Alexion Pharmaceuticals, INC. | $18.84 | 2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $17.26 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.66 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $13.93 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.52 | 2021 | |
| Natus Medical Incorporated | $11.05 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Swift listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.